N-Acetyl Aspartic Acid (NAA) Attenuates Stemness and Epithelial–Mesenchymal Transition and Enhances Radio- and Chemo-Sensitivity in Pancreatic Ductal Adenocarcinoma
Authors:
- Fabiana CrispoFCFabiana Crispo
- Rosa LioyRLRosa Lioy
- Rosalia DieliRDRosalia Dieli
- Mara MartinelliMMMara Martinelli
- Carlo CalabreseCCCarlo Calabrese
- Antonella BianculliABAntonella Bianculli
- Vincenzo De FinaVFVincenzo De Fina
- Grazia LazzariGrazia Lazzari
- Vito MetalloVMVito Metallo
- Donatella TelescaDTDonatella Telesca
- Gennaro LausGLGennaro Laus
- Simona LoperteSimona Loperte
Open Access
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor clinical outcomes and limited responsiveness to conventional treatments. Beyond delayed diagnosis, its high mortality is linked to limited treatment choices and resistance to chemotherapy. Neoplastic cells characterized by stem-like features and epithelial–mesenchymal transition (EMT) activation are crucial drivers of drug resistance and metastatic progression. Consequently, targeting these cellular programs could represent a promising therapeutic strategy for PDAC. N-acetyl-L-aspartic acid (NAA) is an endogenous metabolite, mainly localized in the central nervous system, where it facilitates acetate storage for lipid metabolism. Previous studies established its antineoplastic effect in neuroblastoma, promoting a more differentiated phenotype of cancer cells. Here we investigated the effects of NAA on BxPC-3 pancreatic cancer cells using both 2D and 3D models. NAA treatment induced a dose-dependent reduction in cell proliferation and led to a significant downregulation of stemness-associated surface markers, with concomitant upregulation of E-cadherin. Furthermore, NAA significantly enhanced cellular radiosensitization with a reduction in caveolin-1 and increased efficacy of gemcitabine in PDAC cells. Collectively, these results confirmed the anticancer activity of NAA and provide a rationale for further investigation of its synergistic effects with radiotherapy to yield better PDAC treatments.Keywords
Funding Information
- Ministero della Salute
This publication has 45 references indexed in Scilit:
- Medical management of pancreatic cancer: from personalization to broadening treatment strategiesCancer Treatment Reviews, 2025
- Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular SubtypesJournal of Gastrointestinal Cancer, 2025
- Overcoming therapy resistance in pancreatic cancer: New insights and future directionsBiochemical Pharmacology, 2024
- N-acetyl-aspartate metabolism at the interface of cancer, immunity, and neurodegenerationCurrent Opinion in Biotechnology, 2023
- Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Biological evaluation of [4‐(4‐aminophenyl)‐1‐(4‐fluorophenyl)‐1H‐pyrrol‐3‐yl](3,4,5‐trimethoxyphenyl)methanone as potential antineoplastic agent in 2D and 3D breast cancer modelsArchiv der Pharmazie, 2023
- A Review of Pancreatic CancerJAMA, 2021
- N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitroLife Sciences, 2021
- CD133 as a regulator of cancer metastasis through the cancer stem cellsThe International Journal of Biochemistry & Cell Biology, 2019
- Upregulation of N-acetylaspartic acid alters inflammation, transcription and contractile associated protein levels in the stomach and smooth muscle contractilityMolecular Biology Reports, 2007